Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21)

Modern Pathology

Volumn 17, Issue 10, 2004, Pages 1211-1216

  Khoury, Haytham ^a   Dalal, Bakul I ^b   Nantel, Stephen H ^c   Horsman, Douglas E ^d   Lavoie, Julye C ^c   Shepherd, John D ^c   Hogge, Donna E ^c   Toze, Cynthia L ^c   Song, Kevin W ^c   Forrest, Donna L ^c   Sutherland, Heather J ^c   Nevill, Thomas J ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^c Leukemia/BMT Program of British Columbia   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

AML; Quantitative immunophenotype; t(8; 21)

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; FLUOROCHROME; HLA DR ANTIGEN; MEMBRANE ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; FLUORESCENCE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; KARYOTYPE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; MYELOBLAST; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

ANTIGENS, CD; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; DIAGNOSIS, DIFFERENTIAL; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; PREDICTIVE VALUE OF TESTS; TRANSLOCATION, GENETIC;

EID: 4744344329     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800168     Document Type: Article

References (33)

1. Erickson PF, Robinson M, Owens G, et al. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor. Cancer Res 1994;54:1782-1786.
2. Lutterbach B, Westendorf JJ, Linggi B, et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 1998;18:7176-7184.
3. Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interfers with AML-1-B-dependant transcriptional activation. Mol Cell Biol 1995;15:1974-1982.
4. Yuan Y, Zhou L, Miamoto T, et al. AML-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 2001;98:10398-10403.
5. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization Classification of neoplastic diseases of the hematopoietic and lymphoid tissues. J Clin Oncol 1999;17:3835-3849.
6. Andrieu V, Radford-Weiss I, Troussard X, et al. Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype. Br J Haematol 1996;92:855-865.
7. Byrd JC, Weiss RB. Recurrent granulocytic sarcoma. An unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of neural cell adhesion molecule. Cancer 1994;15:2107-2112.
8. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-4179.
9. Nucifora G, Dickstein JI, Torbenson V, et al. Correlation between cell morphology and expression of the AML1/ ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21). Leukemia 1994;8:1533-1538.
10. Haferlach T, Bennett JM, Loffler H, et al. Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. Leuk Lymphoma 1996;23:227-234.
11. Hurwitz CA, Raimondi SC, Head D, et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 1992;80:3182-3188.
12. Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with t(8;21) chromosomal abnormality: frequent expression of immature B-cell antigens together with stem cell antigen CD34. Blood 1992;80:470-477.
13. Porwit-MacDonald A, Janossy G, Ivory K, et al. Leukemia associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood 1996;87:1162-1169.
14. Khoury H, Dalal BI, Nevill TJ, et al. Acute myelogenous leukemia (AML) with t (8;21)-identification of a specific immunophenotype. Leuk Lymphoma 2003;44:1713-1718.
15. Tabernero MD, Bortoluci AM, Alaejos I, et al. Adult B-ALL with BCR/ABL gene rearrangement displays a unique immunophenotype based on the pattern of CD10, CD34, Cd13 and CD38 expression. Leukemia 2001;15:406-414.
16. De Zen L, Orfao A, Cazzangia G, et al. Quantitative multiparametric immunophenotyping in acute lymphoid leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia 2000;14:1225-1231.
17. Lavabre-Bertrand T, Janossy G, Ivory K, et al. Leukemia-associated changes identified by quantitative flow cytometry: I. CD10 expression. Cytometry 1994;18:209-217.
18. Farahat N, Lens D, Zomas A, et al. Quantitative flow cytometry can distinguish between normal and leukemic B-cell precursors. Br J Haematol 1995;91:640-646.
19. Dworzak MN, Fritsch G, Fleischer C, et al. Comparative phenotype mapping of normal vs malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations. Exp Hematol. 1998;26:305-313.
20. Lubbert M, Herrmann F, Koeffier Ph. Expression and regulation of myeloid-specific genes in normal and leukemic myeloid cells. Blood 1991;77:909-924.
21. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for classification of acute myeloid leukemia. Ann Intern Med 1985;103:621-625.
22. Mitelman F, ed. ISCN, An International System for Human Cytogenetic Nomenclature. Basel: S. Kargar, 1995.
23. Breiman L, Friedman JH, Olshen R, et al. Classification and Regression Trees. Belmont, CA: Wadsworth International Group, 1984.
24. Morton RF, Hebel JR (eds). Screening. In: A Study Guide to Epidemiology and Biostatics, 2nd edn. Gaithersburg, MD: An Aspen Publishers, 1990, pp 63-81.
25. Downing JR. The AML1-ETO chimeric protein transcription factor in acute myeloid leukemia: biology and clinical significance. Br J Haematol 1999;106:296-308.
26. Okuda T, Cai Z, Yang S, et al. Expression of knock-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1998;91:3134-3143.
27. Tsuchiya H, Elsonbaty SS, Ngano K, et al. Acute myeloblastic leukemia (ANLL-M2) with t(8;21(q22;q22) variant expressing lymphoid surface antigens with high number of G-CSF receptors. Leuk Res 1993;17:375-377.
28. Samdani A, Vijapurkar U, Grimm MA, et al. Cytogenetic and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leuk Res 1996;20:175-180.
29. Rhoades KL, Hetherington CJ, Rowley JD, et al. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci USA 1996;93:11895-11900.
30. Mitterbauer M, Kusec R, Schwarzinger I, et al. Comparison of karyotype analysis and RT-PCR for AML1/ETO in 204 unselected patients with AML. Ann Hematol 1998;76:139-143.
31. Rowe D, Cotterill SJ, Ross FM, et al. Cytogenetically cryptic AML1-ETO and CBFβ-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukemia. Br J Haematol 2000;111:1051-1056.
32. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-2333.
33. + normal hematopoietic cells. Blood 1993;82:2069-2078.